Olopatadine
(Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid · KW 4679 · OLOPATADINE · propylidene) · Olopatatadine · Olopatadine(W.S) · Olopatadine 13CD3 · Olopatadine HCl API
Identifikatoren & physikalische Daten
| CAS No. | 113806-05-6 |
|---|---|
| Summenformel | C21H23NO3 |
| Durchschnittliche Molmasse | 337,4 g/mol |
| Monoisotopische Masse | 337,1677936 g/mol |
| SMILES | CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21 |
| InChIKey | JBIMVDZLSHOPLA-LSCVHKIXSA-N |
| PubChem CID | 5281071 |
| ChEMBL | CHEMBL1189432 |
| ChEBI | CHEBI:94593 |
| EC No. | 601-282-3 |
| DTXSID | DTXSID3023390 |
Chemische & physikalische Eigenschaften
| XLogP | 1,5 |
|---|---|
| Polarare Oberfläche (TPSA) | 49,8 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 5 |
| Schwere Atome | 25 |
| Formalladung | 0 |
| Komplexität | 488 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 3.4 |
| Löslichkeit | 3.13e-02 g/LChloroform (Slightly, Heated), DMSO (Slightly) |
| Human Drugs | Breast FeedingLactationAnti-Allergic AgentsAntihistaminesEMA approved medicines: Human medicine |
| Schmelzpunkt | 248 °C188-189.5° |
| Physical Description | Solid |
| Siedepunkt | 523.0±50.0 °C(Predicted) |
| Dichte | 1+-.0.06 g/cm3(Predicted) |
| Lagerbedingungen | Amber Vial, Refrigerator |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | 4.29±0.10(Predicted) |
| Farbe | Pale Yellow to Pale Beige |
| Stabilität | Light Sensitive |
| InChI | InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8- |
| InChIKey | JBIMVDZLSHOPLA-LSCVHKIXSA-N |
| SMILES | O1CC2=CC=CC=C2/C(=C/CCN(C)C)/C2=CC(CC(O)=O)=CC=C12 |
| CAS Datenbank | 113806-05-6(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P203, P264, P270, P273, P280, P301+P316, P318, P321, P330, P391, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Expositionspfade | Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations. |
| Toxizitätsübersicht | Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. |
| Signs and Symptoms | Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion. [Wikipedia] |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)OlopatadineDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation◈ What is olopatadine? |
Anwendungen & Verwendung
Beschreibung
Olopatadine belongs to a kind of antihistamine reagent. It is a relatively selective H1-receptor antagonist and can inhibit the histamine release process from the mast cell, subsequently leading to temporary relief on the negative symptoms associated with histamine. It is devoid of effects on alpha-adrenergic, dopamine and muscarinic type I and II receptors. Its 0.1% solution can be used for topical administration to the eyes. It is indicated for the treatment of itching associated with allergic conjunctivitis.
Verwenden
Olopatadine is a dual acting histamine H1-receptor antagonist and mast cell stabilizer. Antiallergic; antihistaminic.